Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,858.00p

Change Today:

-19.00p
52 Week High: 1,901.50
52 Week Low: 1,264.00

Currency: UK Pounds
Shares Issued: 4,075.43m
Volume: 5,788,984

Market Cap: £75,721m
RiskGrade: 129
Beta: 0.95

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart

6 Month Chart

More GSK charts

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

	Latest	F'cast
Div Yield	0.0%	0.0%
Div Cover	n/a	n/a
Op Mrgn	n/a	n/a
ROCE	n/a

	Latest	F'cast
P/E	n/a	n/a
PEG	n/a	n/a
Pr/Revenue	n/a	n/a
Pr/Book	n/a

	Latest	F'cast
Revenue	n/a	n/a
PBT	n/a	n/a
EPS	n/a	n/a
DPS	n/a	n/a

GSK Fundamentals

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	34,099.00	6,968.00	115.90p	14.5	n/a	-6%	80.00p	4.8%
31-Dec-21	24,696.00	3,599.00	90.56p	22.2	n/a	-22%	80.00p	4.0%
31-Dec-22	29,324.00	5,628.00	139.70p	10.3	0.2	+54%	44.00p	3.1%
31-Dec-23	30,328.00	6,064.00	155.10p	9.4	0.9	+11%	58.00p	4.0%
31-Dec-24	31,376.00	3,477.00	159.30p	8.5	2.8	+3%	61.00p	4.5%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Company Announcements

Director/PDMR Shareholding	13-Jan-2026	15:30	RNS
EC approval of Shingrix PFS	07-Jan-2026	07:05	RNS
Positive phase 3 data for GSK's bepirovirsen	07-Jan-2026	07:00	RNS

More gsk company announcements

GSK ShareCast News

GSK chronic hepatitis B treatment hits goal in t...	07-Jan-2026	ShareCast
Japan approves GSK treatment for severe asthma	06-Jan-2026	ShareCast
GSK's COPD treatment approved by Chinese regulat...	05-Jan-2026	ShareCast

More GSK ShareCast news

GSK Top Newspaper Links

GSK’s hepatitis B drug shows promise in trials	07-Jan-2026	Times
GlaxoSmithKline scraps sale of old drugs	05-Dec-2014	Telegraph
Glaxo sharpens axe to save £1bn as insurers and ...	01-Dec-2014	The Independent

Latest GSK Director Deals

Traded	Action	Notifier	Price	Amount	Value
08-Jan-26	Buy Dividends	Luke Miels	1,894.33p	3	£56.83
22-Dec-25	Buy	Jonathan Symonds	1,810.46p	1,650	£29,872.59
19-Dec-25	Buy	Vishal Sikka	3,629.58p	730	£26,495.90

More GSK director deals

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

GSK Market Data

Currency	UK Pounds
Share Price	1,858.00p
Change Today	-19.00p
% Change	-1.01 %
52 Week High	1,901.50
52 Week Low	1,264.00
Volume	5,788,984
Shares Issued	4,075.43m
Market Cap	£75,721m
Beta	0.95
RiskGrade	129